Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05643235 · ClinicalTrials.gov registry record · NA

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

A NA study of Atrial Fibrillation and Chronic Lymphocytic Leukemia, sponsored by Northwell Health.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05643235: Recruiting NA study of Atrial Fibrillation and Chronic Lymphocytic Leukemia, sponsored by Northwell Health.

NCT05643235 is a NA study of Atrial Fibrillation and Chronic Lymphocytic Leukemia that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 50 participants, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05643235, a NA study of Atrial Fibrillation and Chronic Lymphocytic Leukemia, is actively recruiting participants, sponsored by Northwell Health.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.

Primary Outcome

Incidence of AF lasting 6 or more minutes at 18 months: each arrhythmic episode detected by the patient's device will be reviewed to determine if it is 1) an actual AF episode, and 2) is at least 6 minutes in duration.

Interventions

  • DEVICE Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)

Study Locations (1)

New York

  • Northwell (Northshore University/Long Island Jewish Hospitals) - New Hyde Park

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-01-01
Est. Completion 2030-12-01
Phase NA
Northwell Health

370 total trials

What NCT05643235 shows while recruiting

NCT05643235 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower).

The record links to 5 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Medtronic LINQ-2 Insertable Cardiac Monitor (ILR) is the first listed.

NCT05643235 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05643235 about?

NCT05643235 is a clinical study titled "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors". This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actio...

What is the current status of trial NCT05643235?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-01-01. Estimated completion is 2030-12-01.

What conditions does trial NCT05643235 study?

This clinical trial studies the following conditions: Atrial Fibrillation, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest.

What interventions are being tested in trial NCT05643235?

The interventions under investigation include: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR) (DEVICE).

Who is sponsoring clinical trial NCT05643235?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05643235 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05643235's enrollment target sits among peer trials

50 174th of 202 higher than 25 of 202 other Atrial Fibrillation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05643235, the US trial registry maintained by the National Library of Medicine. NCT05643235 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.